Author: Ravi Shankar

SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) — ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing of its upsized initial public offering of 26,250,000 shares of common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by ADARx. The gross proceeds to ADARx from the offering, before deducting underwriting discounts and commissions and offering expenses payable by ADARx, are expected to be approximately $446.3 million. In addition, the underwriters have a 30-day option to purchase up to an additional 3,937,500 shares of common stock at the public offering price, less underwriting discounts and commissions.

The shares are expected to begin trading on The Nasdaq Global Select Market on September 25, 2026, under the ticker symbol “ADRX.” The offering is expected to close on September 28, 2026, subject to the satisfaction of customary closing conditions.

J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank are acting as lead book-running managers for the offering. LifeSci Capital is acting as a book-running manager for the offering.

Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on September 24, 2026. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a prospectus forming part of the registration statements relating to these securities. When available, copies of the final prospectus relating to the initial public offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at 1-866-718-1649, or by email at prospectus@morganstanley.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; or UBS Securities LLC, Attention: Equity Syndicate, 11 Madison Avenue, New York, NY 10010 or by email at ol-prospectus-request@ubs.com.

In addition, AbbVie has agreed to purchase, in a concurrent private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the Securities Act), a number of shares of ADARx’s common stock that would result in AbbVie owning approximately 4.9% of ADARx’s outstanding shares of common stock following the closing of the initial public offering and the concurrent private placement, at a price of $17.00 per share; provided, however, that in no event would AbbVie purchase more than $100.0 million in shares of common stock. The aggregate gross proceeds to ADARx from the initial public offering and the concurrent private placement, before deducting underwriting discounts and commissions, placement agent fees and other offering and private placement expenses payable by ADARx, are expected to be approximately $535.2 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock. The concurrent private placement is also scheduled to close on September 28, 2026, subject to the satisfaction of customary closing conditions. The closing of the concurrent private placement is contingent and conditioned upon consummation of the initial public offering. However, the closing of the initial public offering is not contingent on the consummation of the concurrent private placement.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.

About ADARx Pharmaceuticals

ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company dedicated to transforming cutting-edge science into next-generation siRNA therapeutics. We have developed technology designed to control the expression of specific disease drivers with highly selective RNA targeted therapies with the goal of delivering life-changing treatments for patients with unmet medical needs. ADARx is focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, developing product candidates for the treatment of complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic (obesity) diseases. In addition to our wholly-owned programs, we have entered into a collaboration and license option agreement with AbbVie to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology.

Forward-Looking Statements

The statements contained in this press release that are not historical facts are forward-looking statements. You can identify forward-looking statements because they contain words such as “believe,” “can,” “estimate,” “expect,” “intend,” “may,” “plans,” “should,” “seeks,” or “will,” or similar expressions which concern ADARx’s strategy, plans, projections or intentions. These forward-looking statements may be included throughout this press release, and include, but are not limited to, statements relating to ADARx’s expected gross proceeds from the initial public offering and concurrent private placement, the expected date for ADARx’s common stock to begin trading on the Nasdaq Global Select Market and the expected closing of the initial public offering and concurrent private placement. By their nature, forward-looking statements are not statements of historical fact or guarantees of future performance and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. ADARx’s expectations, beliefs and projections are expressed in good faith and ADARx believes there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this release. ADARx undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

CONTACT: Contacts

Investors: ir@adarx.com

Media: teri@redhousecomms.com

Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab

FREMONT, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the publication in The Lancet Neurology of the first longitudinal cohort study to evaluate a broad panel of plasma biomarkers in patients receiving anti-amyloid antibody therapy in real-world clinical practice. The study shows that patients with early symptomatic Alzheimer’s disease exhibit markedly different biological responses during treatment with lecanemab.

Led by investigators at Washington University School of Medicine in St. Louis, the study used Alamar’s NULISAseq™ CNS 120 panel to measure 130 plasma proteins spanning amyloid and tau pathology, inflammation, neurodegeneration and synaptic function. Researchers profiled 2,385 samples from 1,967 participants using just 25 microliters of plasma per sample, including patients receiving lecanemab as part of standard clinical care at the Washington University Memory Diagnostic Center and untreated comparison groups from the Knight Alzheimer Disease Research Center.

“Anti-amyloid therapies are now part of routine care, but until now we have had a very narrow window into what is actually happening biologically in the patients receiving them,” said Carlos Cruchaga, PhD, Professor of Psychiatry and director of the NeuroGenomics and Informatics Center at Washington University School of Medicine, and co-senior author of the study. “Our findings show that Alzheimer’s disease and neurodegeneration biomarkers have unique trajectories that capture specific biological process associated with treatment response.”

The proteins associated with amyloid clearance were largely different from those associated with subsequent cognitive decline. The findings show that amyloid clearance and cognitive response reflect different biological processes, helping explain why clearing amyloid does not produce the same degree of clinical benefit in every patient, a pattern observed both in this cohort and across anti-amyloid trials.

Additionally, among 197 patients treated with lecanemab, 34 of the 130 biomarkers measured significantly changed with the number of infusions received, and they did not all move in the same direction. Among the proteins that most strongly distinguished these patients from controls, the brain-derived forms of tau consistently outperformed the same proteins circulating in the periphery, accounting for four of the top five both before treatment and at the last infusion stage. Separating tau that originates in the brain from its systemic counterpart requires both high specificity for the brain-derived form and the sensitivity to detect it at very low concentrations. Measuring these variants alongside more than 100 additional proteins in a single sample is what allowed the investigators to track pathology and treatment response in one assay.

“This study shows why measuring one or two biomarkers is not enough to understand what is happening during treatment and why ultra-high sensitivity matters,” said Yuling Luo, PhD, founder, CEO and chair of Alamar Biosciences. “Alamar’s precision proteomics platform gives researchers a much richer picture of treatment response and helps us understand why patients with the same diagnosis can have very different outcomes.”

About Alamar Biosciences 
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO® HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com. 

Forward Looking Statements 
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the Alamar platform’s capabilities, performance and impact, including its ability to provide richer insights into the treatment response of patients receiving anti-amyloid antibody therapy in real-world clinical practice. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property, and the other risks described in Alamar Biosciences’ filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q filed with the SEC on , 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. 

Media Contact: 
Media@alamarbio.com 

Investor Contact: 
Investors@alamarbio.com 

PERTH, Australia, Sept. 24, 2026 (GLOBE NEWSWIRE) — FireFly Metals Ltd (ASX/TSX: FFM) (FireFly or the Company) advises, in accordance with ASX Listing Rule 3.13.1, that the Annual General Meeting (AGM) of the Company will be held on Tuesday, 24 November 2026.

Details of how shareholders can participate in the AGM will be provided with the Notice of Meeting to be released in due course.

An item of business at the AGM will be the election and re-election of directors. In accordance with article 7.5 of the Company’s Constitution, the closing date for receipt of nominations from persons wishing to be considered for election as a director is Tuesday, 6 October 2026.

Any nominations must be received at the Company’s registered office by 5:00pm (AWST) on Tuesday, 6 October 2026.

For further information regarding FireFly Metals Ltd please visit the ASX platform (ASX:FFM) or the Company’s website https://fireflymetals.com.au/.

Authorised by the Board of Directors.

Laura Noonan-Crowe
Company Secretary        
FireFly Metals Ltd

+61 8 9220 9030
info@fireflymetals.com.au
www.fireflymetals.com.au

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — MAK Acquisition Corp. (TSX: MAK.U) (“MAK”) announced today that it has delivered a notice of breach to Uni Express Inc. (“UniUni”) pursuant to the purchase agreement (the “Purchase Agreement”) among MAK and UniUni governing the proposed reverse take-over by MAK of UniUni (the “Proposed Transaction”). Pursuant to the terms of the Purchase Agreement, UniUni agreed to operate its business within certain specified parameters during the interim period, including a defined maximum cumulative pre-tax loss. Since the announcement of the Proposed Transaction, UniUni’s business and financial performance has deteriorated. MAK believes this constitutes a material breach of the Purchase Agreement.

The delivery of the notice of breach triggers a 15 business day cure period during which UniUni may cure the breach. If UniUni is unable to cure the breach within such period, MAK intends to exercise its rights to terminate the Purchase Agreement.

About MAK Acquisition Corp.

MAK is a special purpose acquisition corporation focused on niche-market businesses providing critical solutions, with strong revenue retention and diversified customer bases. MAK is an exempted company formed under the laws of the Cayman Islands. MAK completed its initial public offering in October 2025 and its securities are listed on the Toronto Stock Exchange under the symbols “MAK.U” and “MAK.WT”. For more information, visit www.makacquisitioncorp.com.

Forward-Looking Information

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “Forward-looking information”) within the meaning of applicable securities laws, including with respect to the Company’s qualifying acquisition. This forward-looking information is identified by the use of terms and phrases such as “may”, “would”, “should”, “could”, “expect”, “intend”, “estimate”, “anticipate”, “plan”, “foresee”, “believe”, or “continue”, the negative of these terms and similar terminology, including references to assumptions, although not all forward-looking information contains these terms and phrases. Economic and geopolitical uncertainties, including regional conflicts and wars, including potential impacts of sanctions, may also heighten the impact of certain factors described herein. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances.

Forward-looking information is based on management’s beliefs and assumptions and on information currently available to management. Although the forward-looking information contained herein is based upon what we believe are reasonable assumptions, investors are cautioned against placing undue reliance on this information since actual results may vary from the forward-looking information.

Forward-looking information involves known and unknown risks and uncertainties, many of which are beyond our control, that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to, the risk that the strategic review process may not result in a transaction on suitable terms, or at all, and the other risk factors described in detail under “Risk Factors” of the Company’s final long form prospectus dated October 22, 2025 and the Company’s preliminary long form prospectus dated June 10, 2026.

Consequently, all of the forward-looking information contained herein is qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments that we anticipate will be realized or, even if substantially realized, that they will have the expected consequences or effects on our business, financial condition or results of operation. Unless otherwise noted or the context otherwise indicates, the forward-looking information contained herein represents our expectations as of the date hereof or as of the date it is otherwise stated to be made, as applicable, and is subject to change after such date. However, we disclaim any intention or obligation or undertaking to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.

For further information, please contact:

Investor Relations Contact:

Ross Marshall
Phone: 416.526.1563
Email: ross.marshall@loderockadvisors.com

VANCOUVER, British Columbia, Sept. 24, 2026 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), Canada’s leading premium licensed producer focused on cultivating and selling premium and super-premium cannabis products, is pleased to report the voting results from its Annual General Meeting of shareholders (the “Meeting”) held earlier today.

A total of 26,439,140 shares were represented in person or by proxy at the Meeting, constituting approximately 39.1% shares represented of the Company’s total issued and outstanding Common shares as of the record date, and voted in favour of all matters brought before the Meeting.

Results of Annual General Meeting

The following matters put forward before shareholders for consideration and approval as set out in Rubicon Organics’ management information circular dated August 19^th, 2026 (the “Circular”) were approved by the shareholders:

• Setting the number of directors of the Company at five;
• Electing Doris Bitz, Jesse McConnell, John Pigott, Margaret Brodie, and Michael Detlefsen as directors of the Company (together the “Board”) for the ensuing year until the next annual meeting of the Company; and
• Appointing PricewaterhouseCoopers LLP as the Company’s auditors for the ensuing year with the Company’s directors authorized to fix their remuneration.

Question	Yes		No		Abstain
Number of Directors at Five (5)	99.8%		0.2%		–
Elect as Director, Doris Bitz	99.2%		–		0.8%
Elect as Director, Jesse McConnell	98.7%		–		1.3%
Elect as Director, John Pigott	92.8%		–		7.2%
Elect as Director, Margaret Brodie	98.6%		–		1.4%
Elect as Director, Michael Detlefsen	93.6%		–		6.4%
Appointment of Auditor	100.0%		–		–

Board Departures

As Len Boggio, Ian Gordon, and Karen Proud did not stand for re-election at the Meeting, they have retired from the Board effective today.

“On behalf of Rubicon Organics and the Board, I would like to thank Len, Ian, and Karen for their dedicated service and valuable contributions to the Company,” said Doris Bitz, Chair of the Board. “Their guidance, experience, and commitment have supported Rubicon Organics through important stages of its development, and we wish each of them the very best in their future endeavours.”

Engagement of Atrium Research Corporation

Rubicon Organics has renewed the services of Atrium Research Corporation (“Atrium”), an independent third-party, to provide research services. Atrium will receive $10,500 per quarter for 12 months beginning on October 1st, 2026. This engagement is subject to TSX-V approval. Atrium and the Company are arm’s-length parties, and neither Atrium nor its insiders holds any shares or options to purchase shares in the issued and outstanding capital of the Company.

ABOUT RUBICON ORGANICS INC.

Rubicon Organics is the Canadian leader in certified organic and premium cannabis. With a vertically integrated model and strong national distribution, the company is scaling a house of trusted, high-performing brands including Simply Bare™ Organics, 1964 Supply Co.™, Wildflower™, and Homestead Cannabis Supply™.

The Company operates two complementary cultivation facilities in British Columbia: the flagship 125,000 square foot Pacifica hybrid greenhouse in Delta and the 47,500 square foot Cascadia indoor facility in Hope. Cascadia is now fully planted and operational, contributing to Rubicon’s total current annual production capacity of approximately 15,500 kilograms of premium cannabis.

With proprietary genetics, award-winning products, and certifications enabling international distribution, Rubicon is positioned at the forefront of the premium cannabis segment.

As the Canadian market continues to evolve and global demand for high-quality cannabis increases, Rubicon Organics’ disciplined execution, brand equity, and consumer loyalty set it apart. The Company’s continued focus on premium quality, thoughtful innovation, and operational excellence has supported steady revenue growth and positive Adjusted EBITDA.

Rubicon Organics represents a rare combination of category leadership, operational strength, and long-term growth potential.

For more information visit www.rubiconorganics.com.

CONTACT INFORMATION

Margaret Brodie
Chief Executive Officer
Phone: +1 (437) 929-1964
Email: ir@rubiconorganics.com

The TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) does not accept responsibility for the adequacy or accuracy of this press release.

Cautionary Statement Regarding Forward Looking Information

This press release contains forward-looking information within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance are “forward-looking statements”. Forward-looking information can be identified by the use of words such as “will”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “may”, “could”, “would”, “should”, “estimates”, “potential” or variations of such words and similar expressions or statements that certain actions, events or results may, could, would, should or will, occur or be achieved.

Forward-looking information is based on management’s current expectations, estimates, projections and assumptions as of the date of this press release, including, without limitation, assumptions regarding the continued service and contributions of the directors elected at the Meeting; the Company’s ability to benefit from the experience and expertise of its Board; the Board’s ability to provide effective governance and strategic oversight; the continued availability of Atrium’s services on the terms described herein; stable market conditions; the Company’s ability to maintain product quality, supply and production levels; and the Company’s ability to successfully execute its business and international expansion strategies.

Forward-looking information in this press release includes, without limitation, statements regarding the contributions of the directors elected at the Meeting; the Board’s role in supporting the Company’s long-term objectives; the renewal of Atrium’s services for a 12-month period; the Company’s ability to expand its presence in regulated international markets; the expected benefits of new product launches; and the Company’s production capacity, revenue growth opportunities and strategic initiatives. These risks and uncertainties include, among others, the risk that anticipated production, yield, operational efficiency, revenue, margin or profitability targets are not achieved; changes in market conditions, consumer demand, competition, regulatory developments, access to capital; and the other risk factors described under the heading “Risk Factors” in Rubicon Organics’ Annual Information Form dated March 23, 2026, filed with the Canadian securities regulatory authorities.

Readers are cautioned not to place undue reliance on forward-looking statements. Although the Company believes that the expectations and assumptions underlying such statements are reasonable, there can be no assurance that they will prove to be accurate, and actual results and future events may differ materially from those anticipated. Except as required by applicable law, Rubicon Organics undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) — Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J. Miller, M.D., M.B.A., M.P.H., to the Company’s Board of Directors, effective immediately. The appointments bring together two accomplished leaders whose complementary experience spans public service, Medicare Advantage, clinical practice, healthcare policy, and business. Senator Torricelli will serve on the Board’s Audit Committee, and Dr. Miller will serve on its Clinical Committee. The appointments fill the Board’s two previously disclosed vacancies and bring the Board to nine directors.

“Today marks an exciting step forward for Clover, and we are thrilled to welcome Bob and Brian to our Board,” said Andrew Toy, Chief Executive Officer of Clover Health. “Bob brings deep ties to New Jersey communities, experience navigating federal policy, and firsthand knowledge of Clover. Brian combines clinical experience with a national perspective on Medicare payment and technology policy. His insights will help us advance care that improves quality, operates more efficiently, and generates meaningful savings. Together, their experience, judgment, and perspectives will strengthen our Board and reinforce our ability to execute with discipline, grow responsibly, and build lasting value for our members, physicians, and shareholders.”

“From the beginning, we built Clover around the belief that some of the hardest problems in healthcare can be solved by challenging long-held assumptions about how healthcare works and care is delivered,” added Vivek Garipalli, Co-founder of Clover Health and Executive Chairperson of the Board. “As Clover grows, it is important that our Board continues to reflect the complexity of the healthcare system we are working to improve and brings together special individuals who understand it from fundamentally different vantage points. Bob and Brian add tremendous depth across public policy, medicine, Medicare and business, and their perspectives will be invaluable as we drive forward on Clover’s mission to Improve Every Life.”

Senator Torricelli brings a distinctive combination of deep New Jersey roots, national policymaking experience, and firsthand knowledge of Clover. For 20 years, he represented New Jersey in the U.S. House of Representatives and the U.S. Senate, where his committee service included the Senate Finance Committee and work on federal financing for healthcare institutions. Following his congressional career, he founded Rosemont Associates, a business strategy firm, and established Woodrose Properties, a real estate development business. Since 2022, he has served on the board of the Company’s insurance subsidiaries, giving him firsthand familiarity with Clover’s business, mission, and approach to Medicare Advantage. Additionally, Senator Torricelli has served as a director of Glassbridge Enterprises, Inc. since February 2017 and previously served as executive vice president and chief operating officer of Aveta, Inc., a healthcare services company. His experience navigating complex policy and business issues will bring a valuable perspective to Clover’s Board and Audit Committee.

“Through my years living in New Jersey and representing its communities in Congress, I have come to know the challenges many seniors face in accessing high-quality, affordable care,” said Senator Torricelli. “Through my service on Clover’s insurance subsidiary board, I have seen the Company’s commitment to meeting those challenges with an ambitious vision and a practical, technology-driven approach. I am honored to join the Board and excited to contribute to its oversight, support this talented team, and help Clover build lasting value for members and shareholders.”

Dr. Miller brings a rare combination of frontline clinical practice and national Medicare policy leadership. A practicing hospitalist at the Johns Hopkins Hospital, an Associate Professor of Medicine at the Johns Hopkins University School of Medicine and Visiting Fellow at the Hoover Institution, Dr. Miller brings to Clover broad ranging regulatory experience spanning the Centers for Medicare & Medicaid Services, the U.S. Food and Drug Administration, and the Federal Trade Commission. He currently serves as Vice Chairman of the Board of Trustees for the North Carolina State Health Plan and as a Commissioner on the Medicare Payment Advisory Commission (MedPAC), the independent, nonpartisan commission that advises Congress on Medicare payment policy. Board-certified in internal medicine and preventive medicine, Dr. Miller offers a practical perspective on improving care delivery and advancing a more effective Medicare program.

“As a practicing physician, I see every day how much better technology can support clinical practice when it delivers the right information at the point of care,” said Dr. Miller. “Medicare needs models that can improve both convenience and quality for consumers, increase efficiency, and generate savings without adding burden for physicians or patients. Clover is building a differentiated model for Medicare Advantage: flexible and nimble, powered by technology, and close enough to physicians and patients to translate innovation into action. I am delighted to join the Board and look forward to helping Clover advance this approach and deliver a better care experience for people on Medicare.”

About Clover Health

Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health’s Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, and in Underserved Populations as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

Investor Relations:
Ryan Schmidt
investors@cloverhealth.com

Press Inquiries:
press@cloverhealth.com

HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) — PEDEVCO Corp. (NYSE American: PED) (“PEDEVCO” or the “Company”), a domestic energy company engaged in the acquisition and development of strategic oil and gas assets in the Rocky Mountain region, today announced that its Interim President, Chief Executive Officer R.T. Dukes and Chief Financial Officer Robert Long, will participate in two upcoming virtual conferences hosted by Lytham Partners and Noble Capital Markets.

Lytham Partners Investor Conference – Fall Event | September 29 – 30, 2026

Management is scheduled to present on Tuesday, September 29, at 12:00 p.m. ET and will host virtual one-on-one meetings with investors on Wednesday, September 30, 2026. Interested parties can register for the event here or view the live presentation by visiting the conference webcast link here.

Noble Capital Markets Emerging Growth Virtual Equity Conference | October 1 – 2, 2026

Management is scheduled to present on Thursday, October 1, 2026, at 10:30 a.m. ET, and will host one-on-one meetings with investors that day. Interested parties can register on Noble’s website at www.nobleconference.com/virtual.

To request a meeting with PEDEVCO’s management team during the conferences, please contact your conference representative or the Company’s investor relations team at PED@elevate-ir.com. After each event, replays of the Company’s presentations will be listed in the investor relations section of its website at www.pedevco.com.

About PEDEVCO Corp.
PEDEVCO Corp. (NYSE American: PED) is a publicly traded energy company engaged in the acquisition and development of strategic oil and gas assets in the Rocky Mountain region. The Company holds over 300,000 net acres, with principal assets in the D-J Basin of southeastern Wyoming and northern Colorado, as well as the Powder River Basin of northeastern Wyoming. PEDEVCO is headquartered in Houston, Texas. More information about PEDEVCO can be found at www.pedevco.com.

Media Contact:
PEDEVCO Corp.
(713) 221-1768
PR@pedevco.com

Investor Relations Contact:
Sean Mansouri, CFA or Laurent Weil
Elevate IR
(720) 330-2829
PED@elevate-ir.com

22^nd Century Group Calls on HHS Secretary Kennedy, Acting FDA Commissioner Diamantas and CTP Director Koplow to Enact and Implement the Reduced Nicotine Content Standard

Administration’s Reported Move to Accelerate Vape and Nicotine Pouch Authorizations Addresses Only Part of the Continuum of Risk

MOCKSVILLE, N.C., Sept. 24, 2026 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today called on political leaders and the U.S. Food and Drug Administration (“FDA”) to enact and implement the proposed “Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products,” 90 Fed. Reg. 5032 (Jan. 16, 2025) (“Proposed Rule”), which remains pending more than eight years after the FDA first announced its intent to act and more than a year after the public comment period closed.

The Company’s call follows a Wall Street Journal report published Wednesday that the Trump administration plans to change federal rules to speed the authorization of tobacco products such as flavored vapes and nicotine pouches, with the FDA expected to announce in coming days that it will revisit the 2021 rule governing premarket review of new tobacco product applications (“U.S. Regulators Plan Major Move to Speed Authorizations of Vapes, Tobacco Pouches,” WSJ, Sept. 23, 2026). 22nd Century supports those efforts and believes they represent only one component of a comprehensive continuum-of-risk strategy to address the harms of tobacco.

The Proposed Rule would establish a maximum nicotine level of 0.70 milligrams per gram of total tobacco in cigarettes, cigarette tobacco, roll-your-own tobacco, most cigars and pipe tobacco, a level low enough to no longer create or sustain addiction. The FDA first issued an advance notice of proposed rulemaking on the subject on March 16, 2018 (83 Fed. Reg. 11818). The Proposed Rule was issued on January 15, 2025, and the comment period closed on September 15, 2025. To date, there is no final rule, no published timeline and no public update from the agency.

What 22nd Century Is Asking Of Federal Policymakers

1. HHS Secretary Kennedy: Direct FDA to prioritize the pending standard, consistent with your stated commitment to tobacco harm reduction and to delivering results for the American people.
2. Acting FDA Commissioner Diamantas: Place the rule back on the FDA’s entry into the Unified Agenda and establish a clear timeline for transmitting a final rule.
3. CTP Director Koplow: Convene the Tobacco Products Scientific Advisory Committee (TPSAC) to review the standard, as FDA stated it intended to do, and complete that step publicly.
4. The Trump Administration: Clear interagency and OMB review rather than allowing the rule to remain undecided and apply the same acceleration to combusted products that it is applying to non-combusted alternatives and to make mandatory that all retailers that sell combustible cigarettes immediately make available, space on their shelves to carry VLNC products.
5. Congress: Members of the Senate Health, Education, Labor and Pensions Committee and the House Energy and Commerce Committee, from both parties, should request a status update from FDA and hold the agency to the 180-day review framework Congress established in the Tobacco Control Act of 2009. Senators who have consistently championed tobacco policy, including Senators Durbin and Merkley, have pressed the agency on the youth implications of its recent flavor decisions; that same scrutiny should extend to finishing a standard FDA itself projects would prevent 48 million young Americans from starting to smoke.

22nd Century notes that the standard is not a partisan question. The policy has been advanced under multiple administrations in both parties since 2009, and the FDA’s own analysis describes it as among the most consequential public health actions available to the agency.

The Evidence Is Irrefutable and the Tool Already Exists

“The evidence is irrefutable, and it has been for years. The FDA’s own scientists have modeled a standard that would prevent approximately 48 million young Americans from starting to smoke and avert 1.8 million tobacco-related deaths by 2060. That proposal and comment period have now been closed for more than one year, while cigarettes remain the leading cause of preventable death in this country. I am asking Secretary Kennedy, Acting Commissioner Diamantas and Director Koplow to finish the job, and I am asking Republicans and Democrats in Congress to insist on a timeline. A reduced nicotine content standard is not a competing policy to the administration’s vape and nicotine pouch efforts, it is the other half of the same objective. Accelerated authorizations for lower-risk alternatives help adults who want to move away from cigarettes; reducing nicotine in combusted products to non-addictive levels helps the adults who are still smoking make that move or quit altogether. Together, those two policies move people down the continuum of risk at population scale, and separately, neither reaches its potential. This is the single most powerful tool available under existing law to accomplish the objectives Washington says it wants, and it can be implemented with products that are already authorized, already in the market and already proven. The mandate should also include a mandatory allocation of space to allow a wider distribution of VLNC products in the combustible space in retail. The only barrier left is the willingness to move forward.” said Larry Firestone, Chief Executive Officer.

Based on the FDA’s population health model published with the Proposed Rule, adopting the standard would:

• Prevent approximately 48 million U.S. youth and young adults from starting to smoke by 2100;
• Prompt more than 12.9 million people who smoke to stop within one year of the rule taking effect, rising to 19.5 million within five years;
• Avert 1.8 million tobacco-related deaths by 2060, rising to 4.3 million by the end of the century;
• Deliver estimated benefits of more than $1.1 trillion per year over the first four decades.

The Proposed Rule bans no product. It caps nicotine — the substance that creates and sustains addiction — and leaves every product category legal, while expressly excluding e-cigarettes, nicotine pouches, heated tobacco products, smokeless tobacco, waterpipe tobacco and premium cigars.

The Technology Is Commercialized, Authorized and Ready

22nd Century’s proprietary non-GMO reduced nicotine tobacco plants are grown using patented technologies that regulate alkaloid biosynthesis, producing tobacco with 95% less nicotine than traditional tobacco. The Company’s VLN^® cigarettes are the only low nicotine combustible cigarettes authorized by the FDA in the United States, carrying authorized claims including “95% less nicotine,” “Helps reduce your nicotine consumption” and “Greatly reduces your nicotine consumption.”

As the Company stated in its comments filed in support of the Proposed Rule, the development and FDA authorization of very low nicotine content tobacco makes it entirely feasible to produce conventionally flavored, consumer-acceptable combusted tobacco products that deliver a customary smoking experience with greatly reduced nicotine levels that comply with the proposed standard. 22nd Century’s wholly owned subsidiary, a leading cigarette manufacturer, produces all VLN^® products at its 60,000 square foot facility in Mocksville, North Carolina, which has the capacity to produce more than 45 million cartons of combusted tobacco products annually, with additional space for expansion.

The Company is also the sole holder of an FDA-authorized reduced nicotine content combustible cigarette in the United States, and in May 2026 the FDA filed for scientific review of the Company’s modified risk tobacco product renewal applications for VLN^® King and VLN^® Menthol King cigarettes and opened a public docket.

Media Availability

Larry Firestone, Chairman and Chief Executive Officer, is available for interviews on the reduced nicotine content standard, the continuum of risk, and the Company’s FDA-authorized VLN^® products. To arrange an interview or request data or background materials, contact investorrelations@xxiicentury.com.

About 22nd Century Group, Inc.

22nd Century Group is pioneering the Tobacco Harm Reduction and Nicotine Reduction Movements by enabling smokers to take control of their nicotine consumption.

Our Technology is Tobacco

Our proprietary non-GMO reduced nicotine tobacco plants were developed using our patented technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant that contains 95% less nicotine than traditional tobacco plants. Our extensive patent portfolio has been developed to ensure that our-high-quality tobacco can be grown commercially at scale. We continue to develop our intellectual property to ensure our ongoing leadership in the tobacco harm reduction movement.

Our Products

We created our flagship product, the VLN^® cigarette using our low nicotine tobacco, to give traditional cigarette smokers an authentic and familiar alternative in the form of a combustible cigarette that helps them take control of their nicotine consumption. VLN^® cigarettes have 95% less nicotine compared to traditional cigarettes and have been proven to allow consumers to greatly reduce their nicotine consumption.

VLN^® and Helps You Smoke Less^® are registered trademarks of 22nd Century Limited LLC.

Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.

Learn more about VLN^® at tryvln.com.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our expectations regarding regulatory enforcement, including our ability to receive authorization or approval for new products, and (ii) our financial and operating performance. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 26, 2026 and Quarterly Reports on Form 10-Q filed May 7, 2026 and August 14, 2026. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact  
Daniel Otto
Chief Financial Officer & Investor Relations
22nd Century Group
investorrelations@xxiicentury.com

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Euro Sun Mining Inc. (TSX: ESM) (“Euro Sun” or the “Company”) is pleased to announce that it has closed its previously announced non-brokered US$3 million strategic equity investment by Urion Investments Holdings Limited (“Urion”), a Trafigura Group company (the “Investment”). For more information about the Investment, please see the Company’s press release dated September 3, 2026, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca.

Pursuant to the Investment, Euro Sun issued 21,974,210 units (each, a “Unit”) at a price of C$0.19 per Unit for gross proceeds of US$3,000,000 (approximately C$4,175,100). Each Unit consists of one common share of the Company (each, a “Common Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant shall be exercisable to acquire one Common Share at a price of C$0.40 per share until September 24, 2030.

The Units were issued pursuant to Ontario Securities Commission Rule 72-503 Distributions Outside Canada and are not subject to a hold period. The listing of the Common Shares and Warrants issued pursuant to the Investment remains subject to the final approval of the Toronto Stock Exchange. No finder’s fees were paid in connection with the Investment. The net proceeds of the Investment are expected to be used for the Rovina Valley Project and general corporate purposes.

In connection with the Investment, Euro Sun and Trafigura Pte Ltd. also entered into an amendment to the binding offtake agreement dated July 10, 2025, as amended and restated December 15, 2025 (the “Offtake Agreement”) to (among other things) provide for an offtake volume of 40% effective upon closing of the Investment. For more information about the Offtake Agreement, please see the Company’s press release dated July 10, 2025, a copy of which is also available under the Company’s SEDAR+ profile at www.sedarplus.ca.

About Euro Sun Mining Inc.

Euro Sun is a Toronto Stock Exchange-listed mining company focused on the exploration and development of its 100%-owned Rovina Valley Project located in west-central Romania, which hosts the second largest copper & gold deposit in Europe. Already granted European strategic status, the Rovina Valley Project is expected to unlock much needed investment and job creation in Hunedoara County and will deliver critical minerals necessary for Europe’s green energy transition.

Further information:

For further information about Euro Sun, or the contents of this press release, please contact Investor Relations at info@eurosunmining.com.

Caution regarding forward-looking information:

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the Investment, such as in respect of the Company’s intended use of net proceeds, receipt of final approval of the Toronto Stock Exchange, and other matters related thereto. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions. Investors are cautioned that forward-looking information is not based on historical facts but instead reflect management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, including: the risk that necessary approvals, including Toronto Stock Exchange approval, may not be obtained; general business, economic, competitive, political and social uncertainties in Romania and the European Union; future commodity prices and market demand; accidents, labour disputes and shortages; risks inherent in the mining industry; and other risks described in the Company’s public disclosure. Undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. This information is qualified in its entirety by cautionary statements and risk factor disclosure contained in filings made by the Company with the Canadian securities regulators, including the Company’s annual information form, financial statements and related MD&A for the financial year ended December 31, 2025, filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.ca.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

MONTREAL, Sept. 24, 2026 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news releases dated July 30, August 14, August 27 and September 10, 2026, the Company voluntarily applied for and the Company’s principal regulator, the British Columbia Securities Commission (the “BCSC”) granted a management cease trade order (the “MCTO”) dated July 30, 2026, under National Policy 12-203 Management Cease Trade Orders (“NP 12-203”) and provided the Company with an extension to file its annual financial statements for the year ended March 31, 2026, including the related management’s discussion and analysis, and Chief Executive Officer and Chief Financial certifications on or before July 29, 2026 (collectively the “Annual Financial Filings”). The deadline has been extended to on or before September 28, 2026.

Pursuant to the MCTO, the Chief Executive Officer and the Chief Financial Officer of the Company may not trade in securities of the Company until such time as the Company files its Annual Financial Filings on or before September 28, 2026, and the Executive Director of the BCSC revokes the MCTO. The MCTO does not affect the ability of shareholders to trade their securities.

The Company expects to file on or before September 28, 2026.

The Company confirms that it will continue to satisfy the provisions of the alternative information guidelines under NP 12-203 by issuing bi-weekly default status reports in the form of news releases until the time it has filed the Annual Financial Filings. The Company confirms that there is no other material information relating to its affairs that has not been generally disclosed.

For further information, please contact:
Jean Gosselin, CFO
Phone: (514) 394-7717
Email: info@prime-group.ca

Forward-Looking Information
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations (including negative and grammatical variations) of such words and phrases or statements that certain acts, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. These statements are based upon assumptions that are subject to significant risks and uncertainties, including risks regarding market conditions, general economic factors and the equity markets generally. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance of Prime may differ materially from those anticipated and indicated by these forward-looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although Prime believes that the expectations reflected in forward-looking statements are reasonable, they can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, Prime disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.